Endocrine Abstracts

Objective: Cinacalcet, a calcimimetic that reduces parathyroid hormone (PTH) secretion and serum calcium (S-Ca) levels by increasing the sensitivity of calcium-sensing receptors has been introduced for the treatment of patients with persistent or recurrent primary hyperparathyroidism (PHPT). Within a prospective, non-interventional cohort study we identified patients with newly diagnosed PHPT who have been started on cinacalcet. Patient characteristics, treatment indications a...

Objective: The Swiss Primary HyperParaThyroidism (PHPT) Cohort Study is an ongoing, prospective, non-interventional project collecting clinical, densitometric, biochemical and outcome data in patients with PHPT. The aims are to describe the profile of these patients particularly neurobehavioral and cognitive symptoms, changes in calcium and PTH over time and treatment modalities.Methods: Patients newly diagnosed with PHPT and with high serum calcium leve...

Objective: To describe the evolution of neurobehavioral and cognitive symptoms in patients with primary hyperparathyroidism as measured by mini-mental state (MMS), Hamilton’s anxiety and depression scale (HADS) and Clock tests. Scores were also compared with biochemical data.Methods: The Swiss primary hyperparathyroidism (PHPT) Cohort Study is an ongoing, prospective, non-interventional national project collecting clinical, biochemical and outcome d...

Objective: Evaluate cinacalcet use and effect based on follow-up within a cohort study of recently diagnosed Primary Hyperparathyroidism (PHPT) patients. Characteristics, treatment indications and biochemical data are presented with measures of cinacalcet efficacy and safety.Methods: The Swiss Primary Hyperparathyroidism Cohort Study is a prospective, non-interventional project to collect clinical, biochemical and outcome data in patients with PHPT initi...